Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-02-21 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于公司解除一致行动关系暨实际控制人变更的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the termination of a concerted action relationship and the change of actual controller of a company (贝达药业股份有限公司). It discusses the legal basis, facts, and conclusions about the change in control and shareholder relationships. There are no financial statements, earnings data, or management discussion of financial results. The document is a standalone legal opinion related to corporate governance and control changes, not a full annual or interim report, nor an announcement of voting results or management changes per se. It fits best under the category of Legal Proceedings Report (LTR) as it deals with legal matters concerning control and shareholder agreements.
2020-02-21 Chinese
关于解除一致行动关系暨实际控制人变更的公告
Major Shareholding Notification Classification · 95% confidence The document is an official announcement from a company regarding the termination of a shareholder agreement (一致行动关系) and the consequent change in the actual controlling shareholder. It details the signing and termination of the agreement, the shareholding structure, and legal opinions confirming the validity of the change. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in control and shareholder relationships, which aligns with announcements about changes in major shareholdings or control. Given the nature of the document, it fits best under Major Shareholding Notification (MRQ). The document length is 2531 characters, which is relatively short and consistent with an announcement rather than a full report.
2020-02-21 Chinese
股东减持股份预披露公告
Major Shareholding Notification Classification · 100% confidence The document is a pre-disclosure announcement regarding a shareholder's plan to reduce their holdings in the company. It details the shareholder's identity, the number of shares held, the planned reduction amount, methods of reduction, timing, and compliance with regulatory requirements. There is no financial performance data, audit information, or management discussion. The document is focused on the shareholder's intention to sell shares, which fits the category of a Major Shareholding Notification rather than a full financial report or other types of filings.
2020-02-21 Chinese
关于BPI-28592药品临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Betta Pharmaceuticals Co., Ltd. regarding the acceptance of their clinical trial application for a new drug BPI-28592 by the National Medical Products Administration of China. It details the drug's research background, regulatory acceptance notice, and potential impact on the company. The document is short (1419 characters), and it is an announcement of a regulatory acceptance related to clinical trial application, not a financial report, management change, or other categories. It does not contain financial data or detailed report content. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-02-19 Chinese
关于对外捐赠用于新冠病毒肺炎疫情防控的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about a charitable donation related to COVID-19 pandemic relief efforts. It includes details about the donation amount, recipients, and the company's statement on the impact of the donation. There are no financial statements, no detailed financial performance data, no regulatory certifications, or meeting materials. The document is short (810 characters) and serves as a disclosure of a corporate social responsibility action. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification either. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2020-02-17 Chinese
关于公司控股子公司诉讼事项的公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement by a company regarding a litigation matter involving its subsidiary. It details the parties involved, the nature of the lawsuit, the claims made, and the potential impact on the company's profits. There are no financial statements, regulatory certifications, or report publications mentioned. The document is a legal proceeding update informing investors and the public about ongoing litigation. Therefore, it fits the category of Legal Proceedings Report (LTR). The document length is 2238 characters, which is consistent with a detailed announcement rather than a full report or a brief notice.
2020-02-16 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.